Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

PathPresenter Empowers Biorepositories to Share Pathology Imaging Data for Biomedical Research

PathPresenter, the global image sharing platform for pathology, announced today a new enterprise workflow platform that empowers biorepositories and databanks to share imaging data with other institutions, AI companies, pharma, and industry for biomedical research. The scalable and secure cloud-based platform makes the imaging data easily available to researchers and provides smart tools to maximize collaborative research for the ultimate benefit of patients and donors. By adopting the PathPresenter platform, biorepositories and organizations have a unique opportunity to generate a return on investment for their digital pathology infrastructure.

Watch a video overview of the new research platform by PathPresenter founder, Dr. Rajendra Singh, here.

Biorepositories play a crucial role in the collection, storage, and delivery of high-quality biospecimens to researchers, while providing honest brokerage services for de-identification of these biospecimens. This facilitates the sharing of knowledge among institutions and promotes meaningful translational biomedical research. The emergence of digital pathology has opened new possibilities for leveraging biorepositories by enabling the sharing of imaging data for research purposes. With the growing use of digital slides in research, these data banks play a vital role in data distribution. However, there has been a lack of well-established, standardized workflows that facilitate the easy distribution of data, collaboration among researchers, and user-friendly tools for working with whole slide images in research.

PathPresenter’s scalable and secure cloud-based digital workflow platform empowers biorepositories to establish next generation repositories of whole slide images. Managed by the organization, PathPresenter allows biorepositories to upload whole slide images along with de-identified tissue metadata such as diagnosis, tumor grade, treatment information, and outcome data. It then provides administrative tools that enable researchers from anywhere in the world to register for access. Once vetted and approved by the organization, research users can search and utilize the data stored in the repository. The platform provides powerful search capabilities that allow researchers to enter specific criteria to find relevant datasets for their research. The data can be downloaded or aggregated in private folders for online research, including the ability to define regions of interest, add annotations, incorporate metadata, and even deploy AI modules. PathPresenter offers features to manage user roles and permissions, such as viewing, editing, or deleting annotations, as well as tools to audit annotator progress. Researchers can build entire research projects on the PathPresenter platform, as well as test AI models without exhausting limited biospecimens.

An early adopter of the PathPresenter research platform was the Food and Drug Administration (FDA) which used it to centralize the collection of tumor infiltrating lymphocytes in breast adenocarcinoma for the validation of de-novo AI technologies. For more information see here: https://www.fda.gov/media/148912/download.

Recently, the Midwestern division of the Cooperative Human Tissue Network (CHTN) and PathPresenter have collaborated to establish an innovative tissue repository. The main goal of this collaborative project is to build an elastic compute cloud-based infrastructure and scalable workflows, ensuring easy accessibility of data to researchers. Additionally, the project aims to provide intelligent tools that enhance collaborative research, with the ultimate objective of utilizing the data to benefit patients and donors.

“The biobank of the future requires not only the collection and timely delivery of high quality biospecimens for researchers, but also simultaneous annotation and de-identification of these biospecimens that can be easily accessible to the research community,” said Dr. Anil Parwani, Principal Investigator for the Midwestern division of CHTN. “We chose PathPresenter as our workflow platform due to a combination of factors, including the tried and tested nature of the viewer, its cloud-based infrastructure to enable easy scaling, tools to centralize collection of annotations and sharing of images, embedded AI that can be released to members as needed, and the flexibility of the platform for customization to the needs of CHTN.”

“PathPresenter has always been focused on creating efficiencies and value for pathology departments/organizations and truly becoming the center of personalized care for our patients,” added Dr. Rajendra Singh, co-founder of PathPresenter. “Our ‘smart’ data distribution workflow is another step in the same direction that will allow biorepositories hosted by pathology departments to securely share data with multiple researchers and help enhance research.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Ariceum Therapeutics’ Targeted Radiopharmaceutical 177Lu-satoreotide Exhibits Promising Clinical Response and Good Tolerability Profile in Patients with Advanced Neuroendocrine Tumours

Satoreotide combines Ariceum’s proprietary peptide satoreotide - a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SSTR2) - with the radioactive isotope ‘payload’ 177Lutetium. SSTR2 is a cell surface protein often overexpressed in certain cancers, including NETs and small cell lung cancer (SCLC).

New Hot Start Isothermal Mixes Boost Sensitivity, Specificity, and Speed of DNA Target Detection

Isothermal mixes are important in a range of isothermal amplification applications, including whole genome amplification, point-of-care assay development and testing, and strand displacement amplification for synthetic biology. However, a common issue with isothermal mixes is non-specific amplification — where primers bind to unintended DNA targets — because amplification often takes place at a fixed temperature which may favour non-specific primer interactions, contrary to PCR. Isothermal mixes can also lead to primer dimer formation, where primers associate with each other and are extended by the polymerase.

Branded Legacy Invests Heavily in Innovation and Growth with $540,000 Expansion

This strategic initiative underscores Branded Legacy's unwavering commitment to innovation, quality, and customer satisfaction. The expansion project is set to infuse over $500,000 worth of inventory into the company, reinforcing its position as a leader in the market.

Cue Biopharma Completes Patient Enrollment in Ph1b Head & Neck Cancer Trial

“Completing the enrollment of the recommended phase 2 dose patient expansion cohort is an important milestone as the data from this trial guides further development plans and associated discussions with the Food and Drug Administration (FDA),” said Daniel Passeri, chief executive officer of Cue Biopharma.

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Michelle Fraser, head of cell and gene therapy at Revvity, underscores the importance of providing broad access to this technology: "Base editing has been extensively demonstrated in numerous studies to safely and precisely control the correction of single base changes at multiple target sites, simultaneously. This streamlined approach simplifies complex multi-gene editing, holding great promise for the development of new cell therapies targeting rare inherited genetic diseases, cancer, and in the creation of universal donor cells as the foundation of allogeneic cell therapies."

By using this website you agree to accept Medical Device News Magazine Privacy Policy